Mon Oct 06 11:40:00 UTC 2025: **News Article Summary:**

**Trump Administration Unveils “TrumpRx” Plan Aiming to Lower Prescription Drug Costs, Questions Remain**

**Washington D.C.** – The Trump administration is launching a new initiative, dubbed “TrumpRx,” aimed at lowering prescription drug prices for Americans. The program, slated to begin in 2026, partners with Pfizer to sell their drugs directly to consumers through a new government website, TrumpRx.gov, bypassing pharmacy benefit managers. The stated goal is to align U.S. drug prices with those in other developed nations, based on the “most-favored-nation” pricing model.

While the administration touts potential savings, particularly for Medicaid patients accessing medications like Eucrisia, Xeljanz, and Zavzpret at discounted rates, the impact and scope of the plan remain unclear. Savings cited focus primarily on those three medications, leaving the broader implications for other drugs and manufacturers uncertain.

Experts also raise concerns about the actual affordability for patients, even with the discounts, particularly for the uninsured. They point out that payments through TrumpRx would likely not count towards deductibles or out-of-pocket maximums for insured individuals, potentially increasing overall healthcare spending.

Additionally, the plan faces scrutiny considering the administration’s past policies, including opposition to the Inflation Reduction Act, which capped insulin costs for Medicare patients, support for Medicaid cuts, and recently imposed pharmaceutical tariffs, which seem contradictory to the goal of lowering drug costs.

While acknowledging the critical need to address high prescription drug costs, experts say the effectiveness and true impact of “TrumpRx” in providing significant relief to American patients remains to be seen.

**Summary of the text:**

The Trump administration announced “TrumpRx”, a program with Pfizer to sell discounted drugs directly to consumers through a government website starting in 2026, aiming for “most-favored-nation” pricing. While touting savings, especially for Medicaid patients and the three stated medications, concerns remain about its overall impact, affordability for the uninsured, and how it fits with the administration’s past health policies, some of which seem to counter efforts to lower drug costs. The success of the program is uncertain.

Read More